PREVIEW: No return to growth for GSK in Q1
This article was originally published in Scrip
GlaxoSmithKline will present its Q1 2013 results on 24 April, with analysts estimating that the UK pharma will report a drop in growth of 5% for the quarter ending 31 March. GSK concedes that there were a number of events in Q1 2012 and during the course of last year that will impact the comparison for Q1 2013.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.